| Outcome Measures: |
Primary: Change in Hemoglobin A1c, Change from baseline in Hemoglobin A1c at the end of study (week 16) between the two drugs, Baseline to week 16|Overall Gastrointestinal tolerability, Incidence of any gastrointestinal adverse events during the whole treatment period., Baseline to week 16 | Secondary: Percentage of patients achieving HbA1c <7%, Percentage of patients achieving HbA1c \<7% at the end of study, Baseline to Week 16|Percentage of patients achieving HbA1c <7% without gastrointestinal effects, Percentage of patients achieving HbA1c \<7% without gastrointestinal effects at the end of study, Baseline to Week 16|Change in Fasting Plasma Glucose (FPG), Change in FPG from baseline to week 16 between the two groups of drugs, Baseline to Week 16|Occurrence of hypoglycemia events, Number of patients reporting hypoglycemia events, Baseline to Week 16|Other Adverse Events (AEs), Number of patients reporting other Adverse Events, Baseline to Week 16|Overall tolerability, Percentage of patients who discontinued study treatment as a result of adverse drug reaction, Baseline to Week 16|Change in Postprandial Plasma Glucose 2-h (PPG), Change in PPG from baseline to week 16 between two groups of drug, Baseline to Week 16|Change in Homeostasis model assessment-β (HOMA- β), Change in HOMA- β from baseline to week 16 between two groups of drug, Baseline to Week 16|Change in Total Cholesterol (TC), Changes from baseline in TC to week 16 between the two groups, Baseline to Week 16|Change in Tri Glycerides (TG), Changes from baseline in TG to week 16 between the two groups, Baseline to Week 16|Change in High Density Lipoprotein-Cholesterol (HDL-C), Changes from baseline in HDL-C to week 16 between the two groups, Baseline to Week 16|Change in Low Density Lipoprotein-Cholesterol (LDL-C), Changes from baseline in LDL-C to week 16 between the two groups., Baseline to Week 16|Change in body weight, Changes from baseline in body weight to week 16 between the two groups, Baseline to Week 16|Overall adherence to Investigational Medicinal Product (IMP), Calculated as overall dosing actually taken IMPs divided by the expected overall dosing as per protocol, Baseline to Week 16|Medication possession ratio (MPR), Calculated as number of days actually taken IMPs divided by the expected number of days as per protocol, Baseline to Week 16
|
